Education
About Us
Working with TipRanks
Follow Us
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
UNCY Stock Chart & Stats
$6.19
-$0.03(-4.01%)
At close: 4:00 PM EST
$6.19
-$0.03(-4.01%)
Day’s Range― - ―
52-Week Range$3.71 - $11.00
Previous CloseN/A
Volume1.16M
Average Volume (3M)483.58K
Market Cap
$133.03M
Enterprise Value$36.34M
Total Cash (Recent Filing)$42.70M
Total Debt (Recent Filing)$265.00K
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Mar 26, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding21,491,396
10 Day Avg. Volume520,403
30 Day Avg. Volume483,585
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)7.16
Price to Sales (P/S)0.00
P/FCF Ratio-1.86
Enterprise Value/Market Cap0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-66.55
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$35.80Price Target Upside478.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Differentiation And Patient AdherenceClinical results indicating fewer and smaller pills with strong patient preference suggest the drug could materially improve adherence versus existing phosphate binders, supporting commercial demand.
Financial Runway And Launch PreparednessA cash position described as sufficient into 2027 combined with a maintained commercial team supports launch readiness and reduces near-term financing risk if approval is obtained.
Regulatory ProgressResubmission of the NDA with targeted FDA feedback on a single deficiency positions the company for an FDA decision in the first half of 2026, improving the likelihood of approval.
Bears Say
Commercial Launch Timing RiskRevised commercialization timing into the second half of 2026 signals uncertainty around market entry and could postpone revenue generation and investor returns.
Lack Of Current RevenueNo reported product revenue underscores reliance on cash reserves and regulatory milestones, increasing vulnerability to delays or additional funding needs.
Manufacturing And Regulatory Compliance RiskA prior FDA-cited manufacturing deficiency that contributed to a Complete Response Letter highlights execution risk in scaling production and meeting regulatory expectations.
Unicycive Therapeutics News
UNCY FAQ
What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $3.71 and its highest was $11.00 in the past 12 months.
What is Unicycive Therapeutics’s market cap?
Unicycive Therapeutics’s market cap is $133.03M.
When is Unicycive Therapeutics’s upcoming earnings report date?
Unicycive Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 66 days.
How were Unicycive Therapeutics’s earnings last quarter?
Unicycive Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.53 by $0.2.
Is Unicycive Therapeutics overvalued?
According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued.
Does Unicycive Therapeutics pay dividends?
Unicycive Therapeutics does not currently pay dividends.
What is Unicycive Therapeutics’s EPS estimate?
Unicycive Therapeutics’s EPS estimate is -0.45.
How many shares outstanding does Unicycive Therapeutics have?
Unicycive Therapeutics has 21,491,396 shares outstanding.
What happened to Unicycive Therapeutics’s price movement after its last earnings report?
Unicycive Therapeutics reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.53. Following the earnings report the stock price went up 7.307%.
Which hedge fund is a major shareholder of Unicycive Therapeutics?
Currently, no hedge funds are holding shares in UNCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Unicycive Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.80 (478.35% Upside)
$35.80 (478.35% Upside)
Hedge Fund Trend
Decreased
By 263.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.17%
12-Months-Change
Fundamentals
Return on Equity
-102.47%
Trailing 12-Months
Asset Growth
31.20%
Trailing 12-Months
Company Description
Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
UNCY Stock 12 Month Forecast
Average Price Target
$35.80
▲(478.35% Upside)
Technical Analysis
Ownership Overview
21.10%
Insiders
2.99% Mutual Funds
23.67% Other Institutional Investors
49.40% Public Companies and
Individual Investors